Valuation : Turn Therapeutics Inc.

Market Cap 293M 253M 237M 216M 407M 28.01B 409M 2.81B 1.1B 14.14B 1.1B 1.08B 46.89B P/E 2026 *
-24.6x
P/E 2027 * -25.2x
Enterprise Value 293M 253M 237M 216M 407M 28.01B 409M 2.81B 1.1B 14.14B 1.1B 1.08B 46.89B EV / Sales 2026 *
586x
EV / Sales 2027 * 58.6x
Free-Float
45.25%
Yield 2026 *
-
Yield 2027 * -
1 day-2.67%
1 week+4.02%
Current month+17.70%
1 month+19.27%
3 months+89.23%
6 months+168.85%
Current year+149.75%
1 week 9.45
Extreme 9.45
10.28
1 month 8.43
Extreme 8.43
10.95
Current year 3.01
Extreme 3.01
11.69
1 year 2.57
Extreme 2.5701
26.5
3 years 2.57
Extreme 2.5701
26.5
5 years 2.57
Extreme 2.5701
26.5
10 years 2.57
Extreme 2.5701
26.5
Manager TitleAgeSince
Chief Executive Officer 48 2015-01-05
Director of Finance/CFO 31 2025-04-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 48 -
Director/Board Member 46 2018-09-30
Director/Board Member 61 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
5/28/26 Don

Chief Executive Officer

-1,200,000 4.0285%
4/2/26 Don

Chief Executive Officer

300,000 1.0188%
4/2/26 Don

Director

300,000 1.0188%
Change 5-day change 1-year change 3-year change Capi.($)
-2.67%+4.02% - - 293M
-1.59%-3.35%+52.37%+91.62% 69.54B
-2.32%+1.16%+44.31%+88.08% 64.97B
-3.57%+0.49%+35.74%+10.62% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-1.51%+0.57%+29.47%-19.55% 19.98B
-3.36%-4.93%+2.30%+549.93% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.82%-1.33%+53.55%+190.03% 28.22B
Weighted average by Cap. -2.68%-1.50%+50.19%+149.11%

Financials

2026 *2027 *
Net sales 500K 431K 404K 369K 695K 47.79M 697K 4.79M 1.87M 24.12M 1.88M 1.84M 79.99M 5M 4.31M 4.04M 3.69M 6.95M 478M 6.97M 47.93M 18.7M 241M 18.77M 18.36M 800M
Net income -11.95M -10.3M -9.65M -8.81M -16.6M -1.14B -16.65M -115M -44.68M -576M -44.86M -43.88M -1.91B -12.32M -10.61M -9.95M -9.08M -17.11M -1.18B -17.17M -118M -46.06M -594M -46.24M -45.23M -1.97B
Net Debt - -
Logo Turn Therapeutics Inc.
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Employees
-
Date Price Change Volume
26-08-28 US$9.840 -2.67% 62,760
26-08-27 US$10.11 +4.98% 47,598
26-08-26 US$9.630 -1.03% 69,360
26-08-25 US$9.730 +0.52% 31,391
26-08-24 US$9.680 +2.33% 70,261
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.840USD
Average target price
26.00USD
Spread / Average Target
+164.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TTRX Stock